SECURITIES AND EXCHANGE COMMISSION
Washington, D. C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): June 16, 2004
INYX, INC.
(Exact name of registrant as specified in its charter)
Nevada 333-83152 75-2870720
- ------ --------- ----------
(State or other jurisdiction (Commission (I.R.S. Employer
of incorporation) File Number) Identification No.)
825 Third Avenue, 40th Floor, New York, NY 10022
------------------------------------------------
(Address of principal executive offices) (Zip Code)
Registrant's telephone number, including area code: (212) 838-1111
Item 5. Other Events and Required FD disclosures
On June 16, 2004, Inyx, Inc. (the "Company") executed a long-term
Supply Agreement with AstraZeneca AB to manufacture AstraZeneca's HFA-version of
Pulmicort, one of the world's leading asthma medicines, for the European market.
The agreement was made effective June 11, 2004. A press release disclosing the
agreement was issued on June 29, 2004.
The press release in Exhibits 99.1 is being furnished, and shall not be
deemed to be "filed", with the SEC. Such exhibit shall not be incorporated by
reference into any filing of the registrant with the SEC, whether made before or
after the date hereof, regardless of any general incorporation language in such
filings.
Item 7. Financial Exhibits, Pro Forma Financial Information and Exhibits.
10.24 Supply Agreement dated June 11, 2004 between AstrraZeneca AB
and the Company
99.1 Press Release of Inyx, Inc. dated June 29, 2004.
SIGNATURES
Pursuant to the requirement of the Securities Exchange Act of 1934, the
registrant has duly caused this report to be signed on its behalf by the
undersigned hereunto duly authorized.
INYX, INC.
By: /s/ Jack Kachkar
------------------------
Jack Kachkar, Chairman
Dated: June 29, 2004
2